Literature DB >> 22811485

Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling.

Yuying Liu1, Grant Bledsoe, Makato Hagiwara, Bo Shen, Lee Chao, Julie Chao.   

Abstract

Kallistatin (KS) levels are reduced in the kidney and blood vessels under oxidative stress conditions. To determine the function of endogenous KS in the renal and cardiovascular systems, KS levels were depleted by daily injection of anti-rat KS antibody into DOCA-salt hypertensive rats for 10 days. Administration of anti-KS antibody resulted in reduced KS levels in the circulation but increased levels of serum thiobarbituric acid reactive substances (an indicator of lipid peroxidation) as well as superoxide formation in the aorta. Moreover, anti-KS antibody injection resulted in increased NADH oxidase activity and superoxide production but decreased nitric oxide levels in the kidney and heart. Endogenous KS blockade aggravated renal dysfunction, damage, hypertrophy, inflammation, and fibrosis as evidenced by decreased creatinine clearance and increased serum creatinine, blood urea nitrogen and urinary protein levels, tubular dilation, protein cast formation, glomerulosclerosis, glomerular enlargement, inflammatory cell accumulation, and collagen deposition. In addition, rats receiving anti-KS antibody had enhanced cardiac injury as indicated by cardiomyocyte hypertrophy, inflammation, myofibroblast accumulation, and fibrosis. Renal and cardiac injury caused by endogenous KS depletion was accompanied by increases in the expression of the proinflammatory genes tumor necrosis factor-α and intercellular adhesion molecule-1 and the profibrotic genes collagen I and III, transforming growth factor-β, and tissue inhibitor of metalloproteinase-1. Taken together, these results implicate an important role for endogenous KS in protection against salt-induced renal and cardiovascular injury in rats by suppressing oxidative stress, inflammation, hypertrophy, and fibrosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22811485      PMCID: PMC3469672          DOI: 10.1152/ajprenal.00257.2012

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  45 in total

1.  Glomerular expression of endothelial nitric oxide synthase in deoxycorticosterone acetate-salt-treated rats.

Authors:  K Tsuchiya; M Naruse; H Nihei
Journal:  Clin Exp Pharmacol Physiol       Date:  2000-10       Impact factor: 2.557

2.  Kallistatin attenuates endothelial apoptosis through inhibition of oxidative stress and activation of Akt-eNOS signaling.

Authors:  Bo Shen; Lin Gao; Yi-Te Hsu; Grant Bledsoe; Makato Hagiwara; Lee Chao; Julie Chao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-08-20       Impact factor: 4.733

3.  Kallistatin stimulates vascular smooth muscle cell proliferation and migration in vitro and neointima formation in balloon-injured rat artery.

Authors:  R Q Miao; H Murakami; Q Song; L Chao; J Chao
Journal:  Circ Res       Date:  2000-03-03       Impact factor: 17.367

4.  Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response.

Authors:  R A Beswick; H Zhang; D Marable; J D Catravas; W D Hill; R C Webb
Journal:  Hypertension       Date:  2001-02       Impact factor: 10.190

5.  Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappaB activation.

Authors:  Hang Yin; Lin Gao; Bo Shen; Lee Chao; Julie Chao
Journal:  Hypertension       Date:  2010-06-21       Impact factor: 10.190

6.  Adrenomedullin gene delivery attenuates hypertension, cardiac remodeling, and renal injury in deoxycorticosterone acetate-salt hypertensive rats.

Authors:  E Dobrzynski; C Wang; J Chao; L Chao
Journal:  Hypertension       Date:  2000-12       Impact factor: 10.190

Review 7.  Molecular basis of renal fibrosis.

Authors:  A A Eddy
Journal:  Pediatr Nephrol       Date:  2000-12       Impact factor: 3.714

8.  Identification of a major heparin-binding site in kallistatin.

Authors:  V C Chen; L Chao; D C Pimenta; G Bledsoe; L Juliano; J Chao
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

Review 9.  Proinflammatory actions of angiotensins.

Authors:  M Ruiz-Ortega; O Lorenzo; Y Suzuki; M Rupérez; J Egido
Journal:  Curr Opin Nephrol Hypertens       Date:  2001-05       Impact factor: 2.894

10.  Reactive-site specificity of human kallistatin toward tissue kallikrein probed by site-directed mutagenesis.

Authors:  V C Chen; L Chao; J Chao
Journal:  Biochim Biophys Acta       Date:  2000-06-15
View more
  19 in total

Review 1.  Protective Role of Kallistatin in Vascular and Organ Injury.

Authors:  Julie Chao; Grant Bledsoe; Lee Chao
Journal:  Hypertension       Date:  2016-07-18       Impact factor: 10.190

2.  Kallistatin levels in HIV-infected patients and effects of statin therapy.

Authors:  Allison Ross Eckard; Soohee Cho; Mary Ann O'Riordan; Grace A McComsey
Journal:  Biomarkers       Date:  2016-09-20       Impact factor: 2.658

3.  Kallistatin modulates immune cells and confers anti-inflammatory response to protect mice from group A streptococcal infection.

Authors:  Shiou-Ling Lu; Chiau-Yuang Tsai; Yueh-Hsia Luo; Chih-Feng Kuo; Wei-Chieh Lin; Yu-Tzu Chang; Jiunn-Jong Wu; Woei-Jer Chuang; Ching-Chuan Liu; Lee Chao; Julie Chao; Yee-Shin Lin
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

4.  Kallistatin protects against bleomycin-induced idiopathic pulmonary fibrosis by inhibiting angiogenesis and inflammation.

Authors:  Xiaoping Huang; Xiao Wang; Xiaolan Xie; Shulan Zeng; Zhaofa Li; Xianxiang Xu; Huiyong Yang; Fei Qiu; Junsheng Lin; Yong Diao
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

5.  Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis.

Authors:  Pengfei Li; Grant Bledsoe; Zhi-Rong Yang; Hongkuan Fan; Lee Chao; Julie Chao
Journal:  Immunology       Date:  2014-06       Impact factor: 7.397

6.  Plasma kallistatin is associated with adiposity and cardiometabolic risk in apparently healthy African American adolescents.

Authors:  Haidong Zhu; Julie Chao; Ishita Kotak; Dehuang Guo; Samip J Parikh; Jigar Bhagatwala; Yutong Dong; Sagar Y Patel; Chris Houk; Lee Chao; Yanbin Dong
Journal:  Metabolism       Date:  2012-11-26       Impact factor: 8.694

7.  Kallistatin protects against sepsis-related acute lung injury via inhibiting inflammation and apoptosis.

Authors:  Wei-Chieh Lin; Chang-Wen Chen; Yu-Wen Huang; Lee Chao; Julie Chao; Yee-Shin Lin; Chiou-Feng Lin
Journal:  Sci Rep       Date:  2015-07-22       Impact factor: 4.379

8.  Clinical Significance of Serum Kallistatin and ENOX1 Levels in Patients with Coronary Heart Disease.

Authors:  Rui Zhang; Zhenjun Ji; Junyan Cai; Yongjun Li; Genshan Ma
Journal:  Med Princ Pract       Date:  2020-07-24       Impact factor: 1.927

9.  Kallistatin - the score beats the marker.

Authors:  Steven Draikiwicz; Kristina Katz; Ashish Tikotekar; Amay Parikh
Journal:  Crit Care       Date:  2013-04-23       Impact factor: 9.097

10.  Protection effect of kallistatin on carbon tetrachloride-induced liver fibrosis in rats via antioxidative stress.

Authors:  Xiaoping Huang; Xiao Wang; Yinghui Lv; Luli Xu; Junsheng Lin; Yong Diao
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.